Trevi Gets A Clap On The Back For Chronic Cough Data
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.